Endocrine Abstracts

Maintaining normal serum and urinary calcium in patients with chronic hypoparathyroidism (cHP) remains a therapeutic challenge. Parathyroid hormone (PTH) replacement therapy is not ideal due to its short half-life and transient activation of the PTH 1 receptor (PTH1R). Eneboparatide is a hybrid analog of PTH and PTH-related peptide specifically designed to induce prolonged activation of the PTH1R. Despite a short half-life, eneboparatide is able to normalize serum and urinary ...

While somatostatin analogs (SSA) are the primary medical therapy for treatment of acromegaly, they fail to normalize insulin-like growth factor 1 (IGF1) levels in the majority of patients when used as monotherapy. Even in patients with controlled IGF1, growth hormone (GH) levels can remain elevated and induce symptoms by interacting with GH receptors throughout the body. AZP-3813 is a 16-amino acid, bicyclic peptide GH receptor antagonist (GHRA) which has been demonstrated to ...